Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) Income from Continuing Operations: 2019-2025

Historic Income from Continuing Operations for Benitec Biopharma (BNTC) over the last 7 years, with Jun 2025 value amounting to -$38.5 million.

  • Benitec Biopharma's Income from Continuing Operations fell 90.10% to -$8.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$38.5 million, marking a year-over-year decrease of 78.26%. This contributed to the annual value of -$38.5 million for FY2025, which is 78.26% down from last year.
  • Latest data reveals that Benitec Biopharma reported Income from Continuing Operations of -$38.5 million as of FY2025, which was down 78.26% from -$21.6 million recorded in FY2024.
  • Benitec Biopharma's 5-year Income from Continuing Operations high stood at -$13.6 million for FY2021, and its period low was -$38.5 million during FY2025.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$21.6 million (2024), whereas its average is -$26.4 million.
  • Data for Benitec Biopharma's Income from Continuing Operations shows a maximum YoY slumped of 78.26% (in 2025) over the last 5 years.
  • Yearly analysis of 5 years shows Benitec Biopharma's Income from Continuing Operations stood at -$13.6 million in 2021, then crashed by 31.50% to -$17.9 million in 2022, then declined by 6.87% to -$19.1 million in 2023, then dropped by 12.93% to -$21.6 million in 2024, then slumped by 78.26% to -$38.5 million in 2025.